Candel Therapeutics (CADL) Equity Average (2020 - 2025)

Candel Therapeutics' Equity Average history runs 6 years deep, the most recent figure standing at $66.0 million for Q4 2025.

• In Q4 2025, Equity Average rose 158.56% year-over-year to $66.0 million; the TTM figure through Dec 2025 stood at $66.0 million (up 158.56% YoY), while the FY2025 annual figure was $59.1 million, up 49.55% from the prior year.
• Equity Average came in at $66.0 million for Q4 2025 at Candel Therapeutics, down from $85.2 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $85.2 million in Q3 2025 to a low of -$35.3 million in Q2 2021.
• A 5-year average of $34.6 million and a median of $39.4 million in 2023 frame the typical range for Equity Average.
• Across the five-year window, Equity Average sank 146.9% in 2024 and soared 4229.35% in 2025, its largest moves.
• Candel Therapeutics' Equity Average stood at $63.6 million in 2021, then slipped by 21.46% to $49.9 million in 2022, then slumped by 64.18% to $17.9 million in 2023, then jumped by 42.79% to $25.5 million in 2024, then jumped by 158.56% to $66.0 million in 2025.
• According to Business Quant data, Equity Average over the past three periods registered $66.0 million, $85.2 million, and $82.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison